All atopic conditions are characterized by type 2 inflammatory responses, as well as common genetic and environmental factors. 1 EoE similarly involves a type 2 inflammatory response and shares genetic susceptibility loci with other atopic diseases. 1,3 Dupilumab, an anti-IL-4 receptor alpha antibody used in AD, is now approved for EoE, suggesting common immunopathology for the conditions. 4 Demonstrating that AD represents a risk factor for EoE may encourage screening for EoE in individuals with AD who develop esophageal symptoms to prevent serious sequelae such as dysphagia, esophageal strictures, and food impaction.Better characterizing the relationship between AD and EoE will facilitate optimal management of both conditions, and future studies may investigate whether certain treatments are ideal in individuals with both AD and EoE.